Should You Buy Tenaya Therapeutics Inc (TNYA) Stock on Friday?

Overall market sentiment has been down on Tenaya Therapeutics Inc (TNYA) stock lately. TNYA receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Tenaya Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TNYA!

See Full TNYA Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With TNYA Stock Today?

Tenaya Therapeutics Inc (TNYA) stock is trading at $2.81 as of 1:39 PM on Friday, Sep 22, an increase of $0.01, or 0.18% from the previous closing price of $2.80. Volume today is below average. So far 135,819 shares have traded compared to average volume of 255,088 shares. The stock has traded between $2.74 and $2.98 so far today. To screen for more stocks like Tenaya Therapeutics Inc click here.

More About Tenaya Therapeutics Inc

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine. Click Here to get the full Stock Report for Tenaya Therapeutics Inc stock.